 BROOKLYN, N.Y., July 23, 2021 GLOBE NEWSWIRE -- Brooklyn ImmunoTherapeutics, Inc. NYSE American: BTX Brooklyn, a biopharmaceutical company focused on exploring the role that cytokine and gene editingcell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that on July 15, 2021, Jay Sial was granted a non-qualified stock option covering 71,000 shares of Brooklyns common stock the Time-Based Option and a restricted stock unit covering 35,700 shares of Brooklyns common stock the RSU. 